Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain phosphoinositide-interacting protein 2 (WIPI2) is a cytosolic scaffolding protein containing seven WD40 repeats that assemble into a β-propeller structure. WIPI2 binds phosphatidylinositol 3-phosphate (PI(3)P) via its conserved FRRG motif and is a critical effector recruited to the nascent autophagosome in response to autophagy induction. At the phagophore, WIPI2 interacts with the ATG16L1–ATG12–ATG5 complex, enabling LC3 lipidation and autophagosome maturation. Loss or mutation of WIPI2 disrupts autophagosome formation and is implicated in developmental disorders, defective pathogen clearance, and may contribute to cancer and neurodegeneration. WIPI2 does not act as a receptor, enzyme, or ion channel, but as a key scaffold and organizer within the autophagy pathway.
Drugs targeting WIPI2 would theoretically act by: - Modulating autophagosome biogenesis - Enhancing or inhibiting ATG16L1–LC3 recruitment to autophagosome membranes - Inhibition by promoting WIPI2 ubiquitination and proteasomal degradation (e.g. CUL4-RING E3 ligase–mediated action during mitosis)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on WD repeat domain phosphoinositide-interacting protein 2 (WIPI2).